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Feline immunodeficiency virus (FIV) causes fatal disease in domestic cats via T cell depletion-mediated immunodeficiency. Pumas and
lions are hosts for apparently apathogenic lentiviruses (PLV, LLV) distinct from FIV. We compared receptor use among these viruses by: (1)
evaluating target cell susceptibility; (2) measuring viral replication following exposure to specific and non-specific receptor antagonists; and
(3) comparing Env sequence and structural motifs. Most isolates of LLV and PLV productively infected domestic feline T cells, but differed
from domestic cat FIV by infecting cells independent of CXCR4, demonstrating equivalent or enhanced replication following heparin
exposure, and demonstrating substantial divergence in amino acid sequence and secondary structure in Env receptor binding domains. PLV
infection was, however, inhibited by CD134/OX40 antibody. Thus, although PLV and LLV infection interfere with FIV superinfection, we
conclude that LLVand PLV utilize novel, more promiscuous mechanisms for cell entry than FIV, underlying divergent tropism and biological
properties of these viruses.
D 2005 Elsevier Inc. All rights reserved.Keywords: Feline; Lentivirus; Receptor; CXCR4; EnvelopeIntroduction
Feline immunodeficiency virus (FIV), like HIV, infects
lymphocytes, results in T cell activation and CD4/CD8
inversion, and ultimately leads to the death of the host due
to immunological exhaustion (Ackley et al., 1990). In this
respect, FIV is unique in its similarity to the pathogenic
primate lentiviruses, as ungulate lentiviruses induce disease
conditions that are more typical of a chronic inflammatory
reaction (reviewed in Miller et al., 2000; Overbaugh et al.,
1997). FIV infection of the domestic cat has been
established as an animal model for AIDS, providing
valuable insights into maternal–fetal and trans-mucosal
transmission, design and testing of anti-retroviral agents,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.07.024
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E-mail address: suev@lamar.colostate.edu (S. VandeWoude).pediatric AIDS, vaccine design, and lentiviral pathogenesis
(reviewed in Bendinelli et al., 1995; Elder et al., 1998;
Willett et al., 1997b).
Serologic surveys of 36 non-domestic feline species have
revealed a minimum of 20 species with antibodies that
cross-react with FIV antigens (Barr et al., 1995; Brown et
al., 1993; Carpenter and O’Brien, 1995; Olmsted et al.,
1992; Troyer et al., 2005). Genetic characterization of the
lentiviruses associated with seroconversion in several of
these species has determined that they are distinct from each
other, related to domestic cat FIV, and have marked intra-
and inter-strain genetic heterogeneity (Barr et al., 1997;
Biek et al., 2003; Brown et al., 1994; Carpenter et al., 1996;
Troyer et al., 2004, 2005). Additionally, sequence compar-
ison of pol sequences from lion and puma lentiviruses (LLV,
PLV; also referred to as FIV-Ple and FIV-Pco) demonstrated
increased diversity, saturation of synonymous sites, and an
increased proportion of substitutions at non-synonymous005) 60 – 76
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infected cats (Biek et al., 2003; Brown et al., 1994;
Carpenter et al., 1996, 1998; Troyer et al., 2004). These
observations suggest that LLV and PLV have been main-
tained in their host lineages longer than FIV has been in
domestic cat populations.
The clinical effects of the FIVs indigenous to wild and
captive non-domestic cat populations have not been well
studied. However, given high seroprevalence rates in the
absence of indications of decreased population fitness, it
appears likely that these infections are not responsible for
high levels of pathology in free-ranging populations (Biek et
al., 2003; Brown et al., 1994; Carpenter et al., 1996).
Additionally, several strains of PLV and LLV can produc-
tively infect domestic cats without resulting in disease,
suggesting that viral as well as host factors mediate
pathogenicity and disease outcome (VandeWoude et al.,
1997a, 2000, 2002, 2003). PLV-1695, an isolate originally
obtained from a British Columbia cougar, is infectious for
domestic cats both parenterally and oronasally, and mucosal
infection was contained in three of four cats in the absence
of specific markers of enhanced host immune response.
Moreover, this isolate demonstrated a greater propensity to
target tissues of the gastrointestinal tract than FIV (Terwee
et al., 2005). These observations support the supposition
that LLV and PLV are less pathogenic and, at least in a
domestic cat model, have significantly different biological
properties than FIV.
The virus–receptor interaction is the primary event in the
process of lentivirus infection, is a critical determinant of
cell tropism, and significantly influences the pathogenesis of
disease. For example, human immunodeficiency virus
targets helper T cells preferentially as these cells express
the viral receptor CD4 (Klatzmann et al., 1984; Maddon et
al., 1986), and variation at the level of viral receptor
specificity underlies the classification of HIV isolates into
syncytium-inducing (SI, X4-adapted strains; Feng et al.,
1996) and non-syncytium-inducing (NSI, R5 strains;
Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996). It is generally
thought that R5 tropic strains are the initial infecting
subtype, and as a result, gastrointestinal tissues expressing
high levels of CCR5 are targeted during initial infection
(Apetrei et al., 2004). As disease progresses, X4-adapted
strains are increasingly isolated, and at end stage of disease
become the primary virus in circulation (Apetrei et al.,
2004). Pathogenicity has been linked to X4 and R5 usage in
both SIV and SIV-HIV recombinant (S/HIV) systems
(Nishimura et al., 2004), and a paucity of CD4+CCR5+
target cells has been correlated with lack of pathogenicity in
natural SIV infections of African Green Monkeys (Allan et
al., 2004). Receptor tropism has been mapped to the Env
region of HIV and SIV, particularly in the V3 loop (Carrillo
and Ratner, 1996; Chesebro et al., 1996; Johnston and
Power, 2002; Kato et al., 1999; Pohlmann et al., 2004;
Speck et al., 1997). Similarly, pathogenicity and cell tropismof FIV have also been linked to env V3 sequence (Hohdatsu
et al., 1996; Hosie et al., 2002; Johnston and Power, 2002;
Lerner and Elder, 2000; Pedersen et al., 2001; Verschoor et
al., 1995). As described above, PLV-1695 localizes in the
gastrointestinal tract tissues and draining lymph nodes in
cats infected parenterally or mucosally, unlike domestic cat
FIV, which is more highly tropic for thymus and bone
marrow (Terwee et al., 2005).
The chemokine receptor CXCR4 has been shown to act
as a co-receptor for FIV, suggesting conservation of
receptor usage between the feline and primate lentiviruses
(Willett et al., 1997a, 1997c, 1998). However, despite the
fact that FIV pathogenicity closely mimics that of HIV, FIV
infection has not been demonstrated to involve interaction
with CD4 and there are no firm data to support a role for
CCR5 in infection of feline cells (Johnston and Power,
1999; Johnston et al., 2001; Lerner and Elder, 2000).
However, CD134/OX40, a member of the tumor necrosis
factor/nerve growth factor-receptor superfamily, has been
identified as a high-affinity receptor for field strains of FIV
(de Parseval et al., 2004a; Shimojima et al., 2004); and
binding mechanics between FIV Env and CD134 mimic
that of HIV Env and CD4 (de Parseval et al., 2005). CD134
is expressed primarily on activated CD4+ T cells, plays a
role in CD4+ expansion, and has been implicated in
modulating cell adhesion in HTLV-1 infection (Uchiyama,
1997; Weinberg et al., 2004). In contrast to FIVs isolated
from cats during the asymptomatic stage of disease, tissue
culture-adapted FIVs appear to utilize CXCR4 as a sole
receptor, as do FIVs isolated from cats with end stage
immunodeficiency disease (Haining et al., 2004). These
findings illustrate a virus–receptor interaction that varies
with pathogenicity as observed in the primate lentivirus
system. For these reasons, we have compared viral–
receptor interactions and env sequences between patho-
genic domestic cat FIV and the presumably less pathogenic
non-domestic feline lentiviruses.
Our initial experimental data suggested that FIV and
PLV have overlapping receptor repertoires, as viral
interference has been observed in vitro and in vivo, and
lion and puma lentiviruses were able to infect domestic cat
PBMC and cell lines (VandeWoude et al., 1997a, 1997b).
The aim of this study was to further characterize receptor
use by these apparently less pathogenic, more highly host-
adapted viruses. We have investigated the use of CD134,
CXCR4, CD4, and CD25 by FIV, PLV, and LLV. We have
also evaluated non-specific binding interactions via heparin
and cyanovirin-N (CVN-N) interference. The data pre-
sented here demonstrate that the non-domestic feline
lentiviruses use different receptors and binding modalities
than FIV. Comparisons of FIV- and PLV-Env amino acid
sequences reveal substantial differences in biochemical
properties in the V3 loop, providing a rationale for
variation in receptor use and suggesting a plausible
mechanism for the observed biological differences noted
among the feline lentiviruses.
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Non-domestic cat lentiviruses replicate in domestic cat cells
We used a representative panel of primary feline
lymphoid cells, lymphoid cell lines, and adherent cells to
assess in vitro growth characteristics of several strains of
LLV and PLV. As previously described, several isolates of
PLV and LLV are able to grow on domestic cat cells in vitro
(Table 1; VandeWoude et al., 2003, 1997a). The feline
lymphoid cell lines 3201 and Mya-1 cells were more likely
to support growth of non-domestic cat lentiviruses than
adherent cell lines. LLV was more difficult to propagate in
vitro than PLV, though several isolates were recovered
following co-cultivation with Mya-1 cells. PLV-1695 and
FIV-C-PG were also able to replicate when grown on puma-
derived PBMC stocks, and conversely, FIV-C-PG was
replication competent on puma-origin PBMC. Thus, domes-
tic cat cell lines can be used as a substrate for non-domestic
cat lentiviral growth, similar to cross-species in vitro
cultures of SIV using Asian macaque or human cells
(Chakrabarti, 2004; Muller and Barre-Sinoussi, 2003).
These results demonstrate that lack of inhibition by specific
antagonists observed in our studies is independent of the
ability of virus to infect cells primarily. Additionally, PLV
could be grown on AH927 cells, which are CXCR4-,
CCR5-, and non-permissive for all strains of FIV tested
(Willett, B.W., personal communication).
CXCR4 antagonists inhibit FIV, but not LLV or PLV,
infection
AMD3100 is a potent CXCR4 antagonist that blocks
infection with CXCR4-dependent strains of HIV and FIV
(Brelot et al., 1999; Donzella et al., 1998; Egberink et al.,
1999; Willett and Hosie, 1999). We therefore examined theTable 1
Growth of cat, lion, and puma lentiviruses in feline cells
Host species Isolate ID Virulence in vivoa
(domestic cat)
Domestic cat FIV-PET +
FIV-GL8 ++
FIV-B 2452 ++
FIV-C PGammer +++
Lion Free-ranging LLV-458 
Columbus OH 772005 nd
Free-ranging 1027, 1029 nd
Puma Florida panther PLV-14 
British Columbia cougar CoLV 
British Columbia cougar PLV-1695 
Replication detected by Mg2+ RT assay or FIV-specific p24 capture ELISA.  = <
10–25 background, ++++ = >25 background, nd = not done. Results based
a In vivo virulence, see (VandeWoude et al., 1997b; VandeWoude et al., Terwe
b 3201—feline lymphosarcoma.
c CrFK—Crandell feline kidney.
d Mya-1—IL-2-dependent feline T cells.effect of AMD3100 on infection with LLV and PLV.
Twenty-four hour exposure to high concentrations of
AMD3100 efficiently and reproducibly inhibited FIV
infection in a dose-dependent manner as previously reported
(Figs. 1A and 3A, Tables 2 and 3). Figs. 1B and C
demonstrate that comparatively, LLV and PLV are not
inhibited by AMD3100 in a dose-dependent manner. In
order to compare results across all three viruses despite
differences in assay technique (ELISA vs. reverse-tran-
scriptase) and wide variation in raw data ranges, viral
growth in the presence of inhibitor is presented as a
percentage of growth in the presence of no AMD control
in Fig. 1D and Figs. 2, 4, 5, and 6. Values from the raw data
for these figures, and subsequent statistical comparisons of
percent inhibition, are presented in Table 3.
Comparisons of time course data between FIV and PLV
exposed to lower concentrations of AMD3100 demonstrated
that although the duration of FIV growth inhibition persisted
for several weeks post-inoculation (Fig. 2A), PLV infection
was only inhibited at doses above 0.25 Ag/ml, and then only
transiently (Fig. 2B). In order to evaluate the possibility that
this transient inhibition was attributable to puma virus
adaptation to domestic cat cells, AMD3100 inhibition was
tested on puma-derived PBMC alongside Mya-1 cells. As
previously noted in Mya-1 cells, FIV-C-PG growth was
completely inhibited, and PLV-1695 growth was transiently
inhibited at the highest concentration. AMD3100 also
blocked FIV infection of puma PBMC; however, in contrast,
PLV-1695 growth was not inhibited by AMD3100 in puma
cells at any concentration (Fig. 3).
Taken collectively, these results reveal that: (1)
AMD3100 potently blocks FIV–CXCR4 interactions;
dilute concentrations of this drug present for 1 h are
capable of significant reduction in viral replication greater
than 2 weeks post-exposure; (2) high concentrations of
AMD3100 are capable of inducing transient reductions inIn vitro tropism
Lion PBMC Cat PBMC 3201b CrFKc Mya-1d
nd +++ +++ ++++ +++
nd +++   +++
nd +++ ++  ++
nd +++   ++
++ ++ ++++ nd ++
    +++
    ++
  ++++ + ++
  ++++ +++ 
+ + ++++ nd ++
2 background; + = 2–5 background, ++ = 5–10 background, +++ =
on at least duplicate estimations monitored for 28 days after infection.
e et al., 2005).
Fig. 1. High dose AMD3100 inhibits FIV more significantly than LLV- or
PLV-growth. (A–C) Triplicate wells containing 3201 Tcells were exposed to
a range of high concentrations of AMD3100, then inoculated with 10 TCID50
FIV-B-2542, LLV-458, or PLV-1695. Cells were washed at 24 h and re-
exposed to the same AMD concentrations as on day 0, providing an extended
period of inhibitor exposure to maximize inhibition of PLV and LLV.
Supernatants were collected bi-weekly for 3 weeks and assayed as described
in Materials and methods. FIV growth was inhibited at all concentrations as
illustrated in panel A for day 10 post-infection (PI). Replication of LLVand
PLV was transiently inhibited (LLVon day 14 and PLVon day 10 PI only),
but the trend was not statistically significant (B, C). Because y-axis scale
range did not allow single graph comparisons, data were converted to %-no-
inhibitor control (as described in Materials and methods) in panel D and in
Figs. 2, 4, 5, and 6. Bars represent average and standard deviation of triplicate
assays. Indicates P < 0.001 (see Table 3).
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derived cells; and (3) FIV infection of puma PBMC-
derived cells is CXCR4 dependent, while PLV infection isnot, as evidenced by response to the presence to CXCR4
antagonist AMD3100.
In order to evaluate the possibility that LLV and PLV
attached to CXCR4 in a manner not disrupted by
AMD3100, we attempted to block viral entry with anti-
CXCR4 antibody. In contrast to AMD3100 interference, this
agent did not inhibit infection by any of the feline
lentiviruses. Others have observed that FIV infection was
not inhibited by anti-CXCR4 antibody, a phenomenon
attributed to the disparate sites of antibody vs. FIV binding
(de Parseval et al., 2004b). SDF1-a, the natural ligand for
CXCR4, inhibited FIV growth as expected, albeit to a lesser
extent than AMD3100. Others have reported weaker
inhibition of FIV growth by SDF1-a than by AMD3100,
which may be observed because of cellular CXCR4
upregulation following exposure to its ligand (Hosie et al.,
1998). PLV growth was not abrogated in the presence of
SDF1-a in multiple trials. LLV was only transiently
inhibited by SDF1-a in 2/5 trials, again demonstrating that
infection of domestic cat cells by non-domestic FIVs is less
sensitive to disruption of CXCR4 binding than the domestic
cat virus (Table 2).
Blocking CD134 significantly inhibits FIV, transiently
inhibits PLV, and does not inhibit LLV in vitro
The recent identification of CD134 as a primary FIV
receptor (de Parseval et al., 2004a; Shimojima et al., 2004)
led us to investigate whether this molecule also served as a
receptor for LLVor PLV cell infection. Several experiments
were conducted to determine the cross reactivity of human
anti-CD134 with domestic cat CD134. Mean fluorescence
intensity (MFI) correlated with antibody concentration over
a range of 1 to 20 Ag/ml on Mya-1 cells (Fig. 4A).
Approximately 13% of Mya-1 cells were labeled using 5
Ag/ml antibody, whereas less than 5% of cells were labeled
when the concentration was decreased to 2 Ag/ml (data not
shown).
Because of a generalized suppression of cell growth
following addition of antibody (which precluded analysis in
concentrations greater than 5 Ag/ml), isotype matched
irrelevant antibody (rather than no antibody) was used in
similar dilutions as non-specific immunoglobulin control.
Growth of FIV-C-PG was consistently and significantly
inhibited on Mya-1 cells by anti-CD134 at a concentration
of 5 Ag/ml compared to irrelevant isotype control antibody
(P < 0.001), but was not inhibited at 2 Ag/ml (Fig. 4B,
Table 3). PLV-1695 was also significantly inhibited by
CD134 antibody at 5 Ag/ml (P < 0.001, Fig. 4B, Table 3)
but not 2 Ag/ml, though percent inhibition was less than for
FIV. LLV-458 was not significantly inhibited by 5 Ag/ml of
anti-CD134 antibody (P = 0.058; Fig. 4B). These data are
similar to observations of AMD3100 inhibition, i.e. strong
support for FIV use of CD134 for cellular entry that cannot
be replicated in identical inhibition experiments with PLV
or LLV.
Table 2
Summary of inhibition studies
Inhibitor Virus Cell type Trials Result
AMD-3100 FIV-B-2542 3201, Mya 3/3 Dose-dependent
inhibition
LLV-458 3201, Mya 2/2 Transient inhibition
PLV-1695 3201, Mya 5/5 Transient inhibition
FIV-C-PG Puma 1/1 Complete inhibition
PLV-1695 Puma 5/5 Transient inhibition
SDF-1a FIV-B-2542 3201,
FePBMC
3/3 Dose-dependent
inhibition
FIV-C-PG Mya 1/1 Dose-dependent
inhibition
LLV-458 3201,
FePBMC
3/5 No inhibition
LLV-458 Mya,
FePBMC
2/5 Transient inhibition
PLV-1695 3201, Mya,
FePBMC
5/5 No inhibition
Anti-CD134 FIV-C-PG Mya 1/1 Dose-dependent
inhibition
PLV-1695 Mya 1/1 Dose-dependent
inhibition
LLV-458 Mya 1/1 Marginal
inhibition
Anti-CD4 FIV-C-PG Mya 1/1 No inhibition
LLV-458 Mya 1/1 No inhibition
PLV-1695 Mya, 3201 3/3 No inhibition
Anti-CD25 FIV-C-PG Mya 1/1 No inhibition
LLV-458 Mya 1/1 No inhibition
PLV-1695 Mya 1/1 No inhibition
Anti-X4 PLV-1695 Mya 2/2 No inhibition
TAK 779 PLV-1695 3201 2/2 No inhibition
Cyanovirin FIV-C-PG Mya 2/2 Dose-dependent
inhibition
PLV-1695 Mya 2/2 No inhibition
LLV-458 Mya 1/1 Dose-dependent
inhibition
Heparin FIV-C-PG Mya 1/1 Dose-dependent
inhibition
LLV-458 Mya, 3201 4/4 Enhancement
PLV Mya, 3201 3/3 Enhancement
Each trial consisted of samples run in triplicate or in sets of five
(cyanovirin, anti-CD134, anti-CD25) at each inhibitor concentration.
Transient inhibition is defined as dose-dependent inhibition noted only at
the earliest timepoint that no-inhibitor control supernatants were RT
positive. Enhancement is defined as inhibitor RT values significantly
greater than no inhibitor control at multiple timepoints post-inoculation.
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inhibit FIV, LLV, or PLV infection
Given that blocking of either CXCR4 or CD134 did not
fully inhibit the non-domestic lentiviruses, other surface
molecules were assayed for a possible role in viral binding.
Mya-1 cells are the only cell type found thus far that are
permissive for all three feline lentiviruses (FIV, PLV, and
LLV). These cells are CD4+CD25+ (data not shown).
Therefore, the possible role of these surface molecules in
viral entry was determined. Incubation of Mya-1 cells with
high, medium, or low concentrations of anti-CD4 and anti-
CD25 either alone or concurrently failed to inhibit FIV, PLV,
and LLV infection (Tables 2 and 3).Heparin inhibits FIV, but enhances LLV and PLV infection
In addition to specific receptor binding, non-specific
interactions between lentiviral envelope and target cell
membranes are involved in HIV, SIV, and FIV infection.
For example, heparin binding has been shown to play a role in
both HIV- and FIV-cellular entry, purportedly through
interactions between basic gp120 (gp95) with anionic cellular
heparin sulfates (de Parseval and Elder, 2001; Ibrahim et al.,
1999; Roderiquez et al., 1995; Tanabe-Tochikura et al.,
1992). To better define non-specific interactions that might
assist infection with LLV and PLV, we infected cells in the
presence of heparin. FIV-C-PG infection was inhibited in a
dose-dependent manner (P < 0.05) by heparin as previously
reported for FIV-34TF10 and FIV-Pet (de Parseval and Elder,
2001). In striking contrast, LLV and PLV infection was not
inhibited, and in fact, viral growth in the face of heparin
exceeded no-heparin controls in 4 of 4 (LLV) or 3 of 3 (PLV)
trials (Fig. 5, Tables 2 and 3), suggesting substantial
differences in non-specific binding interactions between
domestic and non-domestic FIVs.
High mannose glycosylation contributes to FIVand LLV, but
not PLV, Env–receptor interactions
CVN-N, an antibiotic which blocks high-mannose
glycosylation sites on viral Env, interferes with both HIV
and FIV receptor binding and subsequent infection in a non-
specific manner (Barrientos et al., 2003; Bolmstedt et al.,
2001; Dey et al., 2000; Mori and Boyd, 2001; O’Keefe et
al., 2000, 2003), and has recently been shown to interfere
with vaginal and rectal transmission of SIV (Tsai et al.,
2003, 2004). This activity is based upon binding of the
molecule to envelope glycoproteins (specifically high-
mannose oligosaccharides) which interferes with Env–
receptor binding and fusion. Fig. 6 demonstrates the ability
of CVN-N to inhibit infection of LLV on Mya-1 cells,
though results were not strictly dose dependent. FIV and
PLV infection was only inhibited at one dose and timepoint
(Fig. 6, Table 3). However, growth of all three viruses was
blunted in the presence of any concentration of CVN-N.
These results demonstrate that CVN-N stringency and
efficiency of in vitro FIV-, LLV-, or PLV-growth inhibition
are highly variable compared to the specific receptor
antagonists AMD3100 and anti-CD134.
FIV Env sequence and biochemical properties differ
substantially from non-domestic cat lentiviral Env
Given that Env has been shown to be the principal
lentiviral receptor-binding domain, we compared Env
among 2 PLV strains (PLV-1695 and PLV-14), and 2 FIV
strains (Petaluma and C-PG). Addition of lentiviral-Env
sequence obtained from a Pallas’ cat FIV-like virus
(Otocolobus manul, FIV-Oma) assisted in bridging align-
ments of highly divergent regions of FIV- and PLV-Env.
Table 3
Statistical analysis of inhibition studies represented in figures
Virus AMD (Ag/ml) Viral growth Dose vs. control 2-tailed Student’s t Sequential dose 2-tailed Student’s t
FIV 0 0.781 T 0.084
0.3 0.098 T 0.006 P < 0.001 P < 0.05
1.25 0.076 T 0.008 P < 0.001 P < 0.01
5 0.034 T 0.004 P < 0.001
PLV 0 13,061 T 4626
0.3 7533 T 3377 nsd nsd
1.25 9215 T 3261 nsd nsd
5 8901 T 4135 nsd
LLV 0 1138 T 1044
0.3 435 T 296 nsd nsd
1.25 362 T 195 nsd nsd
5 310 T 36 nsd
Virus Antibody Ag/ml Viral growth Dose vs. control 2-tailed Student’s t Sequential dose 2-tailed Student’s t
FIV Control 2 1.48 T 0.41
Anti-CD134 1.20 T 0.27 nsd
Control 5 1.17 T 0.11
Anti-CD134 0.34 T 0.17 P < 0.001 P < 0.001
PLV Control 2 335 T 82
Anti-CD134 352 T 51 nsd
Control 5 394 T 66
Anti-CD134 218 T 40 P < 0.01 P < 0.05
LLV Control 2 677 T 325
Anti-CD134 698 T 263 nsd
Control 5 567 T 120
Anti-CD134 403 T 113 nsd nsd
Virus Treatment Viral growth Dose vs. control 2-tailed Student’s t Sequential dose 2-tailed Student’s t
FIV Control 1.845 T 0.055
Anti-CD4+anti-CD25 1.900 T 0.133 nsd nsd
PLV Control 816 T 152
Anti-CD4+anti-CD25 1013 T 418 nsd nsd
LLV Control 768 T 118
Anti-CD4+anti-CD25 585 T 184 nsd nsd
Virus Heparin (Ag/ml) Viral growth Dose vs. control 2-tailed Student’s t Sequential dose 2-tailed Student’s t
FIV 0 0.374 T 0.260
2.5 0.165 T 0.159 P < 0.05* nsd
5 0.029 T 0.018 P < 0.05* nsd
20 0.022 T 0.055 nsd
PLV 0 511 T 550
2.5 Not done
5 1020 T 1150 nsd nsd
20 646 T 809 nsd nsd
LLV 0 331 T 52
2.5 773 T 491 P < 0.10* nsd
5 508 T 227 nsd
20 508 T 105 P < 0.05* nsd
Virus CV-N (Ag/ml) Viral growth Dose vs. control 2-tailed Student’s t Sequential dose 2-tailed Student’s t
FIV 0 2.19 T 0.25
1 1.72 T 0.70 nsd nsd
10 0.38 T 0.39 P < 0.001 P < 0.01
PLV 0 1683 T 304
1 776 T 599 P < 0.05 nsd
10 1316 T 772 nsd nsd
LLV 0 1473 T 444
1 1226 T 684 nsd nsd
10 497 T 601 P < 0.05 nsd
Statistical comparisons are made using 2-tailed two-sample homoscedastic Student’s t test except where indicated. Values for FIV represent OD450nm ELISA
absorbance values. Values for PLV and LLV represent cpm (counts per minute) in reverse-transcriptase assays.
* Indicates 1-tailed two-sample homoscedastic Student’s t test.
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Fig. 2. Low dose AMD3100 inhibits FIV-, but only transiently inhibits
PLV-growth. Triplicate wells containing 3201 T cells were exposed to a
range of mid-to-low range concentrations of AMD3100, then inoculated
with 10 TCID50 FIV-B-2542 (A) and PLV-1695 (B). Cells were washed at 1
h and fed with AMD-free media. Supernatants were collected and processed
as described in Materials and methods. As previously described, FIV was
inhibited in a dose-dependent manner at all concentrations over a 2 week
growth period (A). PLV replication was initially inhibited in an
approximately does-dependent manner (days 8–10 PI, B) but the trend
did not persist after day 15 PI (growth exceeds no AMD control, B). Bars
represent the average % inhibition of triplicate assays. *Indicates P < 0.05
(see Table 3).
Fig. 3. AMD 3100 inhibits FIV-, but not PLV-, growth in domestic cat cells
and puma-derived cells. Mya-1 (domestic cat) cells or puma PBMC-derived
cells (2  105) were exposed to AMD 3100 at concentrations 5 Ag/ml, 1.25
Ag/ml, and 0.3 Ag/ml, then inoculated with 10 TCID50 FIV-C-PG (A) and
PLV-1695 (B). Experiments were performed in quintiplicate. Cells were
incubated overnight (18 h), washed, and re-exposed to the same
concentrations of AMD 3100 as on day 0. Supernatants were collected
bi-weekly and subjected to reverse transcriptase assay. RT values shown are
from day 10 (Mya-1 cell) or day 14 (puma cells) PI. (A) FIV growth was
significantly inhibited at all concentrations in both cell types. (B) PLV
growth was slightly inhibited at the highest AMD dose in Mya-1 cells, and
not for any AMD concentrations on puma cells. Indicates P < 0.01;
*indicates P < 0.05 (see Table 3).
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particularly those known to be important for receptor
binding. Domestic cat FIV Env differed from non-domestic
cat lentiviruses at approximately 77% of the amino acid
sites. However, the sequence divergence was not uniform in
that regions of relative homology (30–50%) were inter-
rupted by long tracts of unalignable sequence (¨12%
homology). Despite substantial sequence disparity, three
hydrophobic regions were conserved in similar positions
across all feline lentiviruses, allowing more probable align-
ments within the non-homologous regions (Fig. 7). The
V3–V5 region of PLV shared least homology with FIV Env
(corresponding to aa 365 to 627 in the env alignment and
defined in Pancino et al., 1993). In FIV, this region has been
shown to contain the CXCR4 binding site (Willett et al.,
1997a), neutralizing antibody binding sites (Lombardi et al.,
1994, 1995; Tozzini et al., 1993) and several epitopes
important for cell tropism and cell line adaptation (Hohdatsu
et al., 1996; Vahlenkamp et al., 1997; Verschoor et al.,
1995). Within the V3–V5 region, several biochemical
differences are notable that suggest corresponding differ-
ences in secondary structure and function (Table 4). Total
charge was negative in all three non-domestic lentivirus
isolates (1 to 4); this differs substantially from the highlypositive charge noted in this region among domestic cat
FIVs (+8 to +12). Three to 6 additional N-glycosylation
sites were predicted in non-domestic lentiviruses in com-
parison with FIV, and 5–6 fewer cysteine residues were
present in PLV vs. FIV. A similar trend was noted in V3, the
region implicated as receptor binding domain for FIV
(Hohdatsu et al., 1996; Sodora et al., 1994; Verschoor
et al., 1995; Willett and Hosie, 1999). In contrast, the more
conserved regions flanking V3–V5 were more positively
charged in non-domestic lentiviruses than FIV, and con-
tained similar numbers of cysteine residues and putative
N-glycosylation sites (Fig. 7, Table 4). Such differences
indicate that substantial divergence occurs in secondary and
tertiary structures at the receptor-binding region of PLV- vs.
FIV-Env, providing an explanation for the differential
susceptibilities to receptor inhibitors, and supporting the
hypothesis that PLV uses a different receptor to gain cellular
entry than FIV.Discussion
The data presented here strongly support the conclusion
that lion and puma lentiviruses have different mechanisms
Fig. 4. Anti-CD134 inhibits FIV- and PLV- but not LLV-growth. (A) Mya-1
cells were incubated with dilutions of anti-human CD134 (OX40, Ancell
Corporation: clone Ber Act 35) or Isotype control (Mouse IgG1, Ancell
Corporation: clone MOPC 31C) for 30 min at 4 -C, washed, and stained
using Anti-Mouse IgG FITC, and subjected to flow cytometry as described
in Materials and methods. Mean fluorescence intensity decreased with anti-
CD134 concentration. Twelve– fifteen percent of Mya-1 cells were labeled
at 5 Ag/ml compared to <5% at 2 Ag/ml. (B) Mya-1 cells were incubated
with antibodies as described above for 1 h. FIV-C-PG, LLV-458, and PLV-
1695 supernatant stocks were plated at 10 TCID50 on Mya-1 cells in
quintiplicate, incubated at 4 -C for 2 h, 37 -C for 4 h, then washed and re-
fed with media. Supernatants were collected bi-weekly and assayed as
described in Materials and methods. Data for day 6 PI (FIV), day 5 PI
(PLV), and day 8 PI (LLV) are illustrated. Bars represent average of %
inhibition of five assays. 5 Ag/ml aCD134 antibody clearly inhibited both
FIV and PLV growth relative to isotype control antibody over multiple
timepoints, whereas 2 Ag/ml dilutions did not inhibit growth. aCD134
binding to Mya-1 CD134 was able to significantly abrogate FIV and PLV
infection, but not LLV infection in Mya-1 cells. Indicates P < 0.001;
*indicates P < 0.05 (see Table 3).
Fig. 5. Heparin inhibits FIV- but enhances LLV- and PLV-growth. Naı¨ve
Mya-1 cells were incubated with decreasing dilutions of heparin for 1 h.
FIV-C-PG, LLV-458, and PLV-1695 supernatant stocks were then plated on
Mya-1 cells and processed as described in Materials and methods. Data are
shown for day 7 PI for LLV and FIV, day 14 PI for PLV. Bars represent
average of % inhibition in three assays. Whereas FIV replication was
inhibited in a dose-dependent manner, LLV and PLV replication was
enhanced by 100% or more at nearly all heparin concentrations over
multiple timepoints. nd = not done. *Indicates P < 0.05 with 1-tailed t test,
#indicates P < 0.10 (see Table 3).
Fig. 6. Cyanovirin interferes with FIV-, LLV-, and PLV-growth. Naı¨ve Mya-
1 cells were incubated with decreasing dilutions of cyanovirin for 30 min.
FIV-C-PG, LLV-458, and PLV-1695 supernatant stocks were then plated on
Mya-1 cells and processed as described in Materials and methods. Bars
represent average of % inhibition of five assays. FIV and LLV replication
was inhibited at day 4 (FIV) and day 11 (LLV). PLV growth was randomly
inhibited at all cyanovirin concentrations on day 8 PI and not inhibited at
other timepoints. Indicates P < 0.001; *indicates P < 0.05 (see Table 3).
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by the following findings: (a) AMD3100 and SDF-1a only
transiently inhibited PLV and LLV replication relative to
FIV in domestic cat cells, and, in contrast to FIV-C-PG,
PLV-1695 replication was not impaired by AMD3100 in
puma-derived PBMC; (b) replication of LLV and PLV on
Mya-1 cells was not inhibited by heparin; and (c) V3–V5
Env differs substantially between FIV and two strains of
PLV in amino acid sequence, charge, potential post-trans-
lational modification sites, and cysteine content. The role of
CD134 binding in LLV and PLV infection is less clear and
discussed further below.
Puma and lion lentiviruses infected domestic cat PBMC
and T cell lines, particularly Mya-1 cells, demonstrating the
capacity of LLV and PLV to adapt to use domestic cat cell
surface moieties to gain cellular entry. The Mya-1 cell line
was derived from feline blood mononuclear cells, and is
readily infected with primary isolates of FIV (Miyazawa etal., 1989, 1992). Mya-1 cells exhibit IL-2-dependent cell
growth and surface expression of high levels of CD4, CD3,
CD5, CD56, and CD45R as well as the activation markers,
MHC class II and CD25 (Masuoka et al., 1992; Nishimura
et al., 1998; Shimojima et al., 2003). CXCR4, CCR5, IL-10,
IL-12, and IL-4 mRNA are expressed by Mya-1 cells
(Caney et al., 2002; Linenberger and Deng, 1999), but
minimal or no IFN-g expression has been detected by real-
time PCR (J. Terwee, unpublished data). This activated
CD4+ phenotype displayed by Mya-1 cells is compatible
with in vitro propagation of a highly divergent collection of
feline lentiviruses, and is interesting in light of recent
findings that FIV preferentially replicates in, and activates,
cells with a CD4+CD25+ T-reg phenotype (Joshi et al.,
2004; Vahlenkamp et al., 2004). It is also interesting to
speculate that these cells may express low levels of
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species viral replication (Gaddis et al., 2004; Mariani et al.,
2003; Schrofelbauer et al., 2004).
Primary strains of FIV are dependent upon both CD134
and CXCR4 for cell entry (de Parseval et al., 2004a,
2004b; Egberink et al., 1999; Hosie et al., 1998;
Richardson et al., 1999; Shimojima et al., 2004), restricting
their growth to CXCR4+ CD134+ target cells. Tissue
culture adaptation can occur, rendering strains CD134
independent, explaining the variation in cell susceptibilities
noted in Table 1. We found that anti-CD134 and the
CXCR4 inhibitor, AMD3100 markedly disrupted in vitro
infection by FIV-C-PG. Though CXCR4 blocking tran-
siently inhibited LLV and PLV replication, in neither case
was the degree of blocking as consistent and marked as for
FIV. The fact that AMD3100 was ineffective at blocking
PLV-1695 infection in puma-derived cells suggests that
adaptation of PLV in domestic cat cells may confer some
low-level degree of CXCR4 dependency that is rapidly
reversed under pressure of an antagonist. We noted dose-
dependent inhibition of PLV growth in the presence of
anti-CD134 antibody. In light of recent reports that the
binding site for anti-CD134 monoclonal antibody clone
Ber Act 35 does not overlap with FIV-Env binding sites on
CD134 for other FIV strains (de Parseval et al., 2005), and
that two strains of PLV (PLV-14, CoLV) were able to
infect X4CD134 AH927 cells (B. Willett, personal
communication), further investigations using other strat-
egies will be required to clarify the precise association
between LLV and PLV usage of CXCR4 and CD134.
Heparin binding did not interfere with LLV and PLV
infection, in contrast to its ability to block FIV infection in
vitro. The HIV/FIV blocking activity of heparin is thought to
be dependent upon electrostatic interactions between the
basic FIV V3 loop and acidic cell-bound heparin sulfates
(Roderiquez et al., 1995). The V3 binding domain amino acid
sequences of two highly divergent PLVs (PLV-14 and PLV-
1695) have net charges substantially more acidic than FIV. de
Parseval and Elder found that FIV strains with net charges of
+6 or +8 in V3 were more significantly inhibited by heparin
than strains with charges of +4 (de Parseval and Elder, 2001).
Assuming that the V3 loop of PLV functions as a potential
cellular binding domain, the neutral to anionic charge of this
region, combined with the highly divergent amino acid andFig. 7. Predicted amino acid alignment of domestic and non-domestic FIVs show
correlative sites from FIV-Pet Env. These numbers differ between strains because o
672 (610 and 611 in the FIV-pet reference sequence) indicated the transition from
Cysteine residues, FC_, are indicated by pink, and predicted N-glycosylation sites a
contain white letters. Fully conserved amino acid residues are dark grey and boxed
across taxa (>0.5 in the Gonnet PAM250 matrix; Yang, 1997) are in medium grey
the Gonnet PAM250 matrix; Yang, 1997) are in light grey. Regions that have >25%
are indicated by white boxes above the amino acid sequence rows and labeled C1
sequences (light green, entire variable region; dark green, V3 binding region). Epit
rows; stronger binding sites are darker orange. Other structural features defined
(PID), alpha-helix, Trp-rich motif, transmembrane region) have also been indicated
region (residues 365–627), where non-domestic feline lentiviruses have lower chsecondary structure, provides plausible explanation for the
results of inhibition experiments presented here. Our obser-
vation of enhanced growth may occur because neutralization
of anionic heparan sulfates by heparin facilitates binding of a
neutral or anionically charged V3 loop found on PLV, and
possibly LLV, isolates.
Glycosylation of HIV Env is considered a major compo-
nent of cell tropism and receptor targeting, and CVN-N has
been shown to inhibit in vitro FIV infection, inferring a
similar mechanistic property (Dey et al., 2000). Despite the
fact that PLV-1695 Env sequence predicts a significant
number of potential glycosylation sites, CVN-N inhibition
experiments reported were unable to conclusively demon-
strate dose-dependent inhibition of either this virus or LLV.
These ambivalent results are likely attributable to variation in
glycosylation patterns of the virus stocks used, since this
variable is dependent upon the cell in which viral propagation
occurs (Levy, 1998). It is also possible that the selectivity of
CV-N for terminal Man(1–2)Man moieties on high-mannose
Man8 or Man9 glycans precludes inhibition of glycosylation
signatures of the virus stocks used in this study (Bewley and
Otero-Quintero, 2001).
Because the LLV and PLV strains we used for blocking
studies readily infect domestic cat cells, it is difficult to
ascribe our observations to variation between surface
molecules on domestic vs. non-domestic T cells. It is
possible that adaptations in viral genomic sequence and
structure occur when PLV or LLV infect domestic cat cells,
suggested by our experiments in puma-derived PBMC.
Observations by Biek et al. (2003) have demonstrated that
sequence diversity within PLV is very low, and preliminary
studies analyzing a series of PLV-1695 isolates across pol
has not detected sequence selection in tissue culture relative
to wild type virus (Poss et al., data not shown), so such
adaptation events appear to be rare. SIV receptor use has
been assessed based upon infection of cells displaying
human receptor molecules, even though these viruses
originated in African monkeys, and are often been main-
tained in, or adapted to, macaque cells (Chen et al., 1997;
Liu et al., 2000; Vodros et al., 2001, 2003). While lion and
puma candidate receptor proteins require testing to validate
observations made using domestic cat cells, analogy to
primate lentivirus receptor usage would support the validity
of the data presented here.s variable regions of structural homology. Numbers across the top are for
f amino acid mismatches/insertions. A vertical line between residues 671 and
the surface protein (gp120;SU) to the transmembrane protein (gp41:TM).
re shown in yellow. Hydrophobic regions are indicated by black boxes that
with bold letters. Sites that contain strongly conserved amino acid changes
, and those with weakly conserved amino acid changes across taxa (<0.5 in
identity across all feline lentiviruses are considered highly conserved, and
–C6. Variable regions (V1–V9) are defined based on the domestic cat FIV
ope binding sites are indicated by orange boxes above amino acid sequence
in FIV (fusion peptide, leucine zipper, principle immunodominant domain
in white boxes. Light grey numbers highlight the highly divergent V3–V5
arge, fewer cysteines, and more predicted glycosylation sites than the FIVs.
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Table 4
Comparison of Env amino acid sequence properties
V3 binding V3 V3–V5 FPC2 V5-FPC3 FPC3
376–416 354–419 354–567 283–331 568–658 659–687
T N C T N C T N C T N C T N C T N C
FIVA-PET 6 0 2 7 1 3 12 8 14 2 1 3 0 0 0 1 0 0
FIVC-PG 5 0 2 5 1 3 8 10 13 1 1 3 0 0 0 1 0 0
OMA 3 0 1 5 4 1  2 14 8 1 2 3 8 0 0 6 0 0
PLV-14 3 0 1 4 4 1  4 14 8  1 1 3 9 0 0 4 0 0
PLV-1695 4 0 1 4 5 1  1 13 8  1 1 3 5 0 0 3 0 0
FIVA-Pet = FIV Petaluma strain (Olmsted et al., 1989); FIV-C-PG = FIVC-Paddy-Gammer strain (de Rozieres et al., 2004); OMA= Pallas’ cat (O. manul; Barr
et al., 1997) FIV sequence; PLV-14 = Florida Panther FIV sequence (Langley et al., 1994); PLV-1695 = British Columbia cougar FIV sequence (see text).
Amino acid residues corresponding to FIV-Pet sequence are indicated under each column heading; FPC2 = region demonstrating high amino acid sequence
homology among all depicted strains, FPC3 = region demonstrating high amino acid sequence homology among all depicted strains; V5-FPC3 = region
between amino terminus of V5 loop and beginning of conserved region, representing an area of intermediate homology among depicted strains.
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PLV and FIV (VandeWoude et al., 2002), and have here
noted similar in vitro tropisms, leading us to initially
hypothesize that these viruses used similar receptors. The
work presented here does not support this hypothesis. Other
mechanisms underlying viral interference could include: (a)
suppression of superinfection by innate immune mecha-
nisms, similar to observations that HIV-2 prevents super-
infection by R5 strains of HIV-1 by inducing h-chemokine
production, or by actions of intracellular nucleases (Gaddis
et al., 2004; Mariani et al., 2003; Schrofelbauer et al., 2004);
(b) selection of PLV laboratory-cultured isolates with altered
mechanisms for cell entry relative to primary strains
(discussed above); (c) different receptor binding sites on
CD134 or CXCR4 for PLV vs. FIV, attributable to
variations in puma vs. domestic cat molecules; or (d)
disruption of primary PLV viral receptor expression
following initial infection with FIV. Viral glycosylation
sites and point mutations in Env substantially influence
receptor usage among HIV strains (McCaffrey et al., 2004;
Nabatov et al., 2004). It is also possible that the biological
viral isolates used here contained viral quasi-species with
varying receptor affinities due to slight variation in sequence
and N-glycosylation, which do not reflect all subtypes of
PLV and LLV.
Perhaps the most intriguing finding presented here is
the marked differences in FIV, PLV, and FIV-Oma Env
amino acid sequences and alignments. Alterations in the
V3 loop of FIV and HIV have been strongly correlated
with changes in host cell susceptibility, receptor affinity,
neutralizing antibody binding sites, and pathogenicity
(Bjorndal et al., 1997; Carrillo and Ratner, 1996; Chesebro
et al., 1996; Nielsen and Yang, 1998; Nishimura et al.,
1996; Pohlmann et al., 2004; Siebelink et al., 1995; Speck
et al., 1997; Verschoor et al., 1995). Therefore, the high
degree of nucleotide and amino acid divergence noted here
provides an attractive explanation for differential receptor
use by non-domestic cat lentiviruses vs. FIV. It is
interesting that FIV-Oma demonstrates an intermediate
alignment between FIV and PLV, despite the fact that thePallas cat is an Asian cat species vs. the North American
dwelling puma. That the V3–V5 region of PLV more
closely aligns with that of the Pallas cat suggests these
older and more host-adapted viruses might have evolved
convergently to use similar receptor mechanisms which
vary from the more recently emerged and virulent
domestic cat FIV. Further studies comparing amino acid
structure of LLV-Env to PLV and FIV-Oma will allow an
opportunity to further study this trend using an African-
origin FIV. The lack of inhibition of LLV and PLV by
agents that reproducibly inhibit FIV or HIV, together with
substantial differences noted in predicted Env structure will
provide models to relate changes in receptor use and Env
structure to lentiviral pathogenicity.Materials and methods
Cells and viruses
Heparinized blood samples were obtained from cats in a
specific pathogen free breeding colony housed in an
AAALAC International accredited animal facility. Periph-
eral blood mononuclear cells (PBMC) were isolated from
heparinized blood by ficoll gradient centrifugation (Quack-
enbush et al., 1990). Lion and puma naı¨ve PBMC were
provided by Dr. Stephen O’Brien as viably frozen field
samples; Drs. Don Hunter and Caroline Krumm provided
anti-coagulated blood collected from a free-ranging puma.
The feline lymphoid cell lines 3201 (Hardy et al., 1980) and
Mya-1 (Miyazawa et al., 1990, 1992) were grown under
standard conditions (Quackenbush et al., 1990) using
commercially obtained media (Invitrogen Life Sciences,
Carlsbad, CA). Puma-derived PBMC infection experiments
were performed on cells isolated from EDTA anti-coagu-
lated blood using Histopaque (Sigma) and were cultured for
2 months in RPMI-1640 supplemented with Glutamax I,
non-essential amino acids, sodium pyruvate, glucose,
sodium bicarbonate, l-glucose, antibiotics, concanavalin A
at 5 Ag/ml, and recombinant human IL-2 at 100 units/ml.
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blings (2 months). Cells used in experiments described had
been in culture for approximately 4 months and replicated
continuously when grown in IL-2.
PLV-1695 (gift of Dr. Ken Langelier) was amplified in
feline PBMC or Mya-1 cells as previously described
(Terwee et al., 2005; VandeWoude et al., 1997b). LLV-
458 and PLV-14 supernatants were obtained from Dr.
Stephen J. O’Brien, and stocks were amplified in domestic
cat PBMC or Mya-1 cells in vitro (VandeWoude et al.,
1997a, 1997b). Supernatants were harvested at peak RT
activity (Willey et al., 1988). FIV-B-2542 and FIV-C-Paddy
Gammer (FIVC-PG) stocks were generated in feline PBMC
or Mya-1 cells using standard conditions (Quackenbush et
al., 1990). These two field strains of FIV have been shown
in previous studies to infect cats mucosally and trans-
placentally and cause immunological and clinical decline
(Allison and Hoover, 2003; Burkhard et al., 1997; Diehl et
al., 1996; Obert and Hoover, 2000; Pedersen et al., 2001;
Rogers and Hoover, 1998, 2002). FIV-GL8 and FIV-PET
were prepared as previously described (Willett et al.,
1997a). Stocks were titrated on the targeted cell type for
each assay using standard techniques (Harper, 1993) and
used in inhibition experiments at concentrations of 20–40
TCID50.
In vitro tropism studies
Supernatants grown in naı¨ve cat, lion, or puma PBMC
were co-cultivated on feline PBMC, CrFK, 3201, or Mya-
1 cells. Cells were plated in 24-well plates in the
appropriate media at a concentration of 2  106/ml. Viral
stocks were added to constitute 10% total media volume.
Twenty-five to 50% of the supernatants were collected and
cells re-fed with fresh media bi-weekly for 4 weeks.
Supernatants were subjected to microtiter RT assay as
previously described (VandeWoude et al., 1997a; Willey et
al., 1988).
Inhibitors
AMD3100 was a gift from Dr. Lou Hegedus (Colorado
State University, Fort Collins, CO, Department of Chem-
istry). Recombinant human SDF-1a was obtained from
Peprotech (Rocky Hill, NJ). Mouse monoclonal antibodies
were obtained as follows: anti-human CXCR4, catalogue #
MAB-172, R&D Systems (Minneapolis, MN); anti-feline
CD4 clone 3-4F4, Southern Biotech (Birmingham AL);
anti-human CD134 (OX40) clone Ber Act 35; mouse IgG1
(clone MOPC 31C, Ancell Corporation, Bayport, MN);
and IgG2a (Unlb Clone HOPC-1 Southern Biotech,
Birmingham AL) isotype control. Porcine heparin (sodium
salt), Grade I-A was purchased from Sigma Aldrich (St
Louis, MO). Cyanovirin-N (CVN, purified recombinant
expressed in E. coli) was a gift from Dr. John Elder (The
Scripps Research Institute, La Jolla, California, Departmentof Molecular Biology). Anti-feline CD25 monoclonal
antibody was a gift of Dr. Wayne Tompkins (North
Carolina State University, Raleigh, NC, Immunology
Program).
Inhibition assays
Inhibition of virus-CXCR4 binding was attempted using
the CXCR4 inhibitor AMD3100, monoclonal antibody
anti-CXCR4 172, and SDF-1a. Virus was plated in
constant concentration against serial dilutions of inhibitor,
or in one AMD3100 experiment, virus was titrated against
a constant concentration of inhibitor. CD4, CD25 and
CD134 inhibition studies were performed with anti-feline
CD4 or CD25 monoclonal antibody or anti-human CD134.
Serial-dilutions of heparin and CVN were used for non-
specific blocking studies as outlined below. Anti-CD4,
anti-CD25, and anti-CD134 binding limits for serial
dilutions were determined by flow cytometric analysis as
described below. Positive controls consisted of FIV when
appropriate (i.e. CXCR4 and CD134 inhibition) or flow
cytometric analysis of cells labeled with the concentrations
of antibodies used (i.e. CD4, CD25, CD134). Negative
controls consisted of virus without inhibitor, cells without
virus, or isotype control antibodies (for CD4, CD25,
CD134, CXCR4).
The standard format for inhibition assays was as
follows: (1) target cells (Mya-1, 3201, or PBMC) were
plated at 2  105 cells/well in replicates of 3–5 in
lymphocyte or 3201 media; (2) inhibitors were added to
2 final concentration in ranges shown previously to
inhibit FIV infection (AMD3100, SDF1a, heparin, CVN;
Donzella et al., 1998; Egberink et al., 1999) or in
concentrations determined using flow cytometry to eval-
uate limiting dilution (anti-CD134, anti-CD4, anti-CD25);
(3) 20–40 TCID50 viral supernatant stocks were added to
wells in an equal volume to each well, or naı¨ve
supernatant was added as negative control; cells were
incubated at 37 -C with 5% CO2 for 24 h, then washed
and re-fed with media alone. In CVN, CD25, CD4, and
CD134 inhibition studies, protocols were modified so that
cells were exposed to inhibitor for 1 h at 37 -C followed
by addition of virus and a 2-h, 4 -C incubation. Cells
were then again incubated at 37 -C for 4 h. We employed
this protocol to synchronize viral-cell binding in each
culture and eliminate any potential viral binding kinetic
differences in the experiments. Cells were then centri-
fuged at 400  g, washed and re-plated with media; CVN
was re-added to cultures in the original exposure
concentration.
Supernatants were collected bi-weekly starting at day 3
and assayed for virus as described below for most samples;
in some cases FIV supernatants were collected daily.
Samples were considered positive when OD450 nm read-
ings or RT values exceeded 2.5 media control in at least
two samples, and was confirmed at later timepoints during
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between viruses and assays, which precluded multi-viral
comparisons on one graph. Therefore, percent inhibition
was calculated as [((NRx  Neg)  (Rx  Neg)) / (NRx 
Neg)] * 100, where NRx = cells with virus and no inhibitor;
Neg = cells with no virus; Rx = cells with virus and
inhibitor. Percent of no-inhibitor control was calculated as
100%  (percent inhibition). Percent inhibition was
determined starting at timepoints where positive controls
were clearly above background as described until 3–4
weeks post-inoculation. Multiple replications were per-
formed for several inhibitors as listed in Table 2 to verify
reproducibility of results using multiple viral strains or cell
types. Statistics presented in Table 3 were calculated using
raw data subjected to two-sample homoscedastic Student’s t
test analysis (Microsoft Excel, Microsoft Corporation,
Redmond, WA).
Viral detection
The presence of FIV in culture supernatants was detected
using p24 antigen capture ELISA (Dreitz et al., 1995).
Previous studies have demonstrated that PLV and LLV are
not detected by this ELISA assay (VandeWoude et al.,
1997a). LLV and PLV growth was detected using a reverse
transcriptase microtiter assay as described with the excep-
tion that 3 Al of RT reaction was spotted on Wallac DEAE
nylon microbeta counter filter paper and read with a Wallac
microbeta counter (Wallac/Perkin Elmer, Wellesley, MA;
Willey et al., 1988).
Flow cytometry
2.0  105 Mya-1 cells were plated and centrifuged at
800  g in a 96-well-v-bottom plate (Costar, Corning Inc,
Corning NY). Mouse monoclonal anti-human CD134 (1
mg/ml), anti-feline CD4 (0.5 mg/ml), or anti-feline CD25
(cell culture supernatant) described above was diluted in
flow buffer at concentrations from 1:50 to 1:1000 (anti-
CD134) or 1:100 to 1:10000 (anti-CD4, anti-CD25) in a
final volume of 0.2 ml with 2  105 cells. Reactions were
incubated at 4 -C for 30 min, then washed twice. Cells
were incubated with 1:100 dilution of fluorescein iso-
thiocyanate (FITC)-conjugated sheep anti-mouse IgG
(Sigma, St Louis, MO), for 30 min. After washing,
samples were passed through an EPICS XL-MCL flow
cytometer (Beckman Coulter, Miami, FL). Cells stained
with isotype control antibodies were used to set analysis
gates. Results following acquisition of 10,000 events were
analyzed using FlowJo software (Tree Star, Inc., San
Carlos, CA).
PLV-1695 env sequencing
Genomic DNA was extracted with QIAamp DNA blood
mini kit (Qiagen, Valencia CA) from Mya-1 cells persis-tently infected with PLV-1695. Nested PCR were employed
to amplify a 4.5 kb fragment that encompasses the 3V coding
regions of the PLV genome. Reactions employed ExTaq
DNA polymerase (Takara Mirus Bio, Madison WI) accord-
ing to manufacturer’s protocol. PCR conditions were 3 min
at 94 -C, and then 35 cycles of 94 -C for 30 s, 30 s annealing
at 54 -C for first round PCR and 52 -C for second rounds, a
70 -C extension for 4 min 30 s, and a final 10 min extension
at 70 -C. First round PCR primers were 3PLV11F, 5V
GCCGGAACCTACAGACCCCTTAT 3V and 3PLV12R, 5V
TTTGTTCTGCCCATTCTCCTATTG 3V and second round
primers were 3770F, 5VAGAGAAGAAGATGCTAGATAT-
GATTT 3V and 3PLV14R, 5VACAGATATCTTTGAAGG-
GACACAT 3V. PCR products were gel isolated and cloned
into pDrive (Qiagen) and used to transform TOP10 cells
(Invitrogen Corp, Carlsbad CA). Plasmid DNA was recov-
ered from transformed colonies and sequenced.
Comparison of domestic and non-domestic feline lentiviral
Env regions
env nucleotide sequences for FIV-Petaluma (accession
no. M25381; Olmsted et al., 1989), FIV-C36 (accession no.
AY600517; de Rozieres et al., 2004), Pallas’ cat lentivirus,
FIV-Oma (accession no. U56928; Barr et al., 1997), and
PLV-14 (accession no. U03982; Langley et al., 1994) were
obtained from GenBank. Predicted amino acid sequences
were aligned with those of PLV-1695 (see above) in Clustal
X (Thompson et al., 1997) using the PAM 350 protein
weight matrix (Yang, 1997) and realigned manually. The
predicted secondary structure of these amino acid sequences
including N-glycosylation sites (Gupta et al., in preparation;
Gupta and Brunak, 2002; Gupta et al., 2002), protein
domains (Corpet et al., 1998), disulfide bonds (Rost et
al., 2004), hydrophobic regions, and net charge was
determined using the PredictProtein server; http://
www.embl-heidelberg.de/predictprotein/, NetNGlyc 1.0
server; http://www.cbs.dtu.dk/services/NetNGlyc/, and Iso-
electric Plot; http://www-biol.univ-mrs.fr/d_abim/d_docs/
doc-tab-pk.html.Acknowledgments
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